Literature DB >> 19038000

Using gene expression profiling to identify a prognostic molecular spectrum in gliomas.

Mitsuaki Shirahata1, Shigeyuki Oba, Kyoko Iwao-Koizumi, Sakae Saito, Noriko Ueno, Masashi Oda, Nobuo Hashimoto, Shin Ishii, June A Takahashi, Kikuya Kato.   

Abstract

Histopathological classification of gliomas is often clinically inadequate due to the diversity of tumors that fall within the same class. The goal of the present study was to identify prognostic molecular features in diffusely infiltrating gliomas using gene expression profiling. We selected 3456 genes expressed in gliomas, including 3012 genes found in a gliomal expressed sequence tag collection. The expression levels of these genes in 152 gliomas (100 glioblastomas, 21 anaplastic astrocytomas, 19 diffuse astrocytomas, and 12 anaplastic oligodendrogliomas) were measured using adapter-tagged competitive polymerase chain reaction, a high-throughput reverse transcription-polymerase chain reaction technique. We applied unsupervised and supervised principal component analyses to elucidate the prognostic molecular features of the gliomas. The gene expression data matrix was significantly correlated with the histological grades, oligo-astro histology, and prognosis. Using 110 gliomas, we constructed a prediction model based on the expression profile of 58 genes, resulting in a scheme that reliably classified the glioblastomas into two distinct prognostic subgroups. The model was then tested with another 42 tissues. Multivariate Cox analysis of the glioblastoma patients using other clinical prognostic factors, including age and the extent of surgical resection, indicated that the gene expression profile was a strong and independent prognostic parameter. The gene expression profiling identified clinically informative prognostic molecular features in astrocytic and oligodendroglial tumors that were more reliable than the traditional histological classification scheme.

Entities:  

Mesh:

Year:  2008        PMID: 19038000     DOI: 10.1111/j.1349-7006.2008.01002.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  16 in total

Review 1.  Recent advances in understanding nuclear size and shape.

Authors:  Richik N Mukherjee; Pan Chen; Daniel L Levy
Journal:  Nucleus       Date:  2016-03-10       Impact factor: 4.197

Review 2.  Biology, genetics and imaging of glial cell tumours.

Authors:  C Walker; A Baborie; D Crooks; S Wilkins; M D Jenkinson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

3.  Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.

Authors:  Angel Mauricio Castro-Gamero; Kleiton Silva Borges; Daniel Antunes Moreno; Veridiana Kill Suazo; Mayara Missono Fujinami; Rosane de Paula Gomes Queiroz; Harley Francisco de Oliveira; Carlos Gilberto Carlotti; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Invest New Drugs       Date:  2013-01-09       Impact factor: 3.850

4.  Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma.

Authors:  Tsuyoshi Fukushima; Makiko Kawaguchi; Kenji Yorita; Hiroyuki Tanaka; Hideo Takeshima; Kazuo Umezawa; Hiroaki Kataoka
Journal:  Neuro Oncol       Date:  2011-10-03       Impact factor: 12.300

Review 5.  The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.

Authors:  J G Perez; N L Tran; M G Rosenblum; C S Schneider; N P Connolly; A J Kim; G F Woodworth; J A Winkles
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

6.  Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

Authors:  Lale Erdem-Eraslan; Lonneke A Gravendeel; Johan de Rooi; Paul H C Eilers; Ahmed Idbaih; Wim G M Spliet; Wilfred F A den Dunnen; Johannes L Teepen; Pieter Wesseling; Peter A E Sillevis Smitt; Johan M Kros; Thierry Gorlia; Martin J van den Bent; Pim J French
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

7.  Conversion of a molecular classifier obtained by gene expression profiling into a classifier based on real-time PCR: a prognosis predictor for gliomas.

Authors:  Satoru Kawarazaki; Kazuya Taniguchi; Mitsuaki Shirahata; Yoji Kukita; Manabu Kanemoto; Nobuhiro Mikuni; Nobuo Hashimoto; Susumu Miyamoto; Jun A Takahashi; Kikuya Kato
Journal:  BMC Med Genomics       Date:  2010-11-10       Impact factor: 3.063

8.  Gene expression profiles of gliomas in formalin-fixed paraffin-embedded material.

Authors:  L A M Gravendeel; J J de Rooi; P H C Eilers; M J van den Bent; P A E Sillevis Smitt; P J French
Journal:  Br J Cancer       Date:  2011-12-20       Impact factor: 7.640

9.  SCG3 Protein Expression in Glioma Associates With less Malignancy and Favorable Clinical Outcomes.

Authors:  Yi Wang; Nan Ji; Junmei Wang; Jingli Cao; Deling Li; Yang Zhang; Liwei Zhang
Journal:  Pathol Oncol Res       Date:  2021-02-26       Impact factor: 3.201

10.  Proteomic analysis of glioma chemoresistance.

Authors:  Kyoungho Suk
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.